Saturday, 14 May 2022 14:17

Anticoagulation news items. Weeks commencing 2nd and 9th May 2022

Association of bleeding severity with mortality in extended thromboprophylaxis of medically ill patients in the MAGELLAN and MARINER trials

Circulation
Post hoc analysis of rivaroxaban studies found all-cause mortality (ACM) for patients with nonmajor clinically relevant bleeding (BL) vs. no BL not increased in MARINER (HR 0.43;P=0.235) but increased in MAGELLAN (1.74;P=0.021). Major BL was not linked to higher ACM incidence.

 

Small volume intramuscular injections in people taking oral anticoagulants

Specialist Pharmacy Service
This resource covers guidance and evidence, practical advice for healthcare professionals, product prescribing information, advice on vaccines, including influenza and covid-19, and includes section on injecting hydroxocobalamin subcutaneously, and possible alternatives.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services